您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > BMS 270394
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
BMS 270394
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
BMS 270394图片
CAS NO:262433-54-5
包装与价格:
包装价格(元)
1mg电议
5mg电议

产品介绍
A RARγ agonist
Cas No.262433-54-5
Canonical SMILESOC(C1=CC(F)=C(NC([C@H](O)C2=CC(C(C)(C)CCC3(C)C)=C3C=C2)=O)C=C1)=O
分子式C23H26FNO4
分子量399.5
溶解度DMSO: 20 mg/ml
储存条件-20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

BMS 270394 is an agonist of retinoic acid receptor γ (RARγ; EC50= 30 nM in a transactivation assay) and the active enantiomer of BMS 189961 .1It is selective for RARγ over RARβ (EC50= 400 nM) and is inactive at RARα. BMS 270394 synergizes with paclitaxel to inhibit the growth of MCF-7 breast and OVCAR-3 ovarian cancer, as well as SqCC/Y1 head and neck squamous cell carcinoma, cells.2

1.Klaholz, B.P., Mitschler, A., Belema, M., et al.Enantiomer discrimination illustrated by high-resolution crystal structures of the human nuclear receptor hRARγProc. Natl. Acad. Sci. USA97(12)6322-6327(2000) 2.Vivat-Hannah, V., You, D., Rizzo, C., et al.Synergistic cytotoxicity exhibited by combination treatment of selective retinoid ligands with taxol (Paclitaxel)Cancer Res.61(24)8703-8711(2001)